Your browser is no longer supported. Please, upgrade your browser.
SNCA Seneca Biopharma, Inc. daily Stock Chart
Seneca Biopharma, Inc.
Index- P/E- EPS (ttm)-3.39 Insider Own4.21% Shs Outstand17.30M Perf Week3.19%
Market Cap13.28M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float8.86M Perf Month-6.90%
Income-12.80M PEG- EPS next Q- Inst Own8.40% Short Float0.19% Perf Quarter2.00%
Sales0.02M P/S702.29 EPS this Y41.50% Inst Trans164.50% Short Ratio0.01 Perf Half Y-40.82%
Book/sh1.23 P/B0.62 EPS next Y- ROA-168.50% Target Price- Perf Year-88.11%
Cash/sh0.57 P/C1.33 EPS next 5Y- ROE-212.70% 52W Range0.50 - 9.89 Perf YTD-22.89%
Dividend- P/FCF- EPS past 5Y43.80% ROI- 52W High-92.62% Beta1.71
Dividend %- Quick Ratio8.80 Sales past 5Y- Gross Margin- 52W Low46.00% ATR0.06
Employees5 Current Ratio8.80 Sales Q/Q140.80% Oper. Margin- RSI (14)44.02 Volatility8.88% 6.56%
OptionableNo Debt/Eq0.00 EPS Q/Q72.80% Profit Margin- Rel Volume0.14 Prev Close0.76
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume3.16M Price0.73
Recom- SMA20-7.70% SMA50-11.85% SMA200-24.08% Volume456,112 Change-4.38%
May-27-20 11:00AM  
May-22-20 11:45AM  
May-15-20 08:00AM  
Apr-09-20 08:00AM  
Apr-07-20 08:00AM  
Apr-03-20 08:00AM  
Apr-01-20 06:30PM  
Mar-27-20 07:00AM  
Feb-13-20 12:50PM  
Jan-17-20 02:00PM  
Jan-10-20 11:00AM  
Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidates include NSI-189, a chemical entity, which has been completed Phase II clinical trials for the treatment of major depressive disorder; and NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.